PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Han X, Vesely MD, Yang W, Sanmamed MF, Badri T, Alawa J, López-Giráldez F, Gaule P, Lee SW, Zhang JP, Nie X, Nassar A, Boto A, Flies DB, Zheng L, Kim TK, Moeckel GW, McNiff JM, Chen L. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science Translational Medicine 2019, 11 PMID: 31826980, DOI: 10.1126/scitranslmed.aax1159.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsArthritisAutoantibodiesAutoimmunityDendritic CellsHumansInflammationInterferon Type ILupus Erythematosus, CutaneousLupus Erythematosus, SystemicMembrane ProteinsMice, Inbred BALB CMice, Inbred MRL lprMyeloid CellsNeutrophilsReceptors, Antigen, T-CellSignal TransductionTerpenesUp-RegulationConceptsPlasmacytoid dendritic cellsDiscoid lupus erythematosusSystemic lupus erythematosusCutaneous lupus lesionsPD-1HLupus erythematosusLupus lesionsAutoimmune diseasesKO miceT cellsMyeloid cellsHuman systemic lupus erythematosusBALB/c backgroundCutaneous lupus erythematosusInappropriate immune responseProgression of lupusSystemic autoimmune diseaseImmune cell expansionSuppression of autoimmunityAgonistic monoclonal antibodyDeath-1 homologCutaneous lupusProinflammatory neutrophilsDendritic cellsDLE lesionsCutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies.
Little AJ, Vesely MD. Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies. The Yale Journal Of Biology And Medicine 2020, 93: 81-95. PMID: 32226339, PMCID: PMC7087060.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous lupus erythematosusDevelopment of CLEDisease pathogenesisAdaptive immune componentsClinical trial landscapeUnmet medical needFuture therapeutic strategiesPromising clinical trialsFuture pathogenesisLupus erythematosusSignificant morbidityAutoimmune diseasesImmune cellsClinical trialsCurrent treatmentTrial landscapeImmune componentsTherapeutic strategiesDrug AdministrationMedical needDiseasePathogenesisEnvironmental triggersTherapyType IHIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease
Little A, Chen P, Vesely M, Khan R, Fiedler J, Garritano J, Islam F, McNiff J, Craft J. HIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease. JCI Insight 2023, 8: e166076. PMID: 37526979, PMCID: PMC10543720, DOI: 10.1172/jci.insight.166076.Peer-Reviewed Original ResearchConceptsCutaneous lupus erythematosusLupus skin diseaseT cellsSkin diseasesCytotoxic signatureInflammatory infiltrateHIF-1Tissue damageKidney-infiltrating T cellsSkin-infiltrating T cellsAutoimmune skin diseaseHIF-1 inhibitionSkin tissue damageLupus erythematosusSystemic diseaseTissue inflammationGranzyme BMouse modelInflammatory gene programDiseaseProtein levelsInfiltratesSkin environmentGene programPresent studySpatial transcriptomics in inflammatory skin diseases using GeoMx digital spatial profiling: a practical guide for applications in dermatology
Cho C, Haddadi N, Kidacki M, Woodard G, Shakiba S, Yıldız-Altay Ü, Richmond J, Vesely M. Spatial transcriptomics in inflammatory skin diseases using GeoMx digital spatial profiling: a practical guide for applications in dermatology. JID Innovations 2025, 5: 100317. DOI: 10.1016/j.xjidi.2024.100317.Peer-Reviewed Original ResearchDigital spatial profilingInflammatory skin diseaseGeoMx Digital Spatial ProfilerSkin diseasesDiscoid lupus erythematosusNanoString GeoMx Digital Spatial ProfilingImmune milieuImmune microenvironmentLichen planusLupus erythematosusSingle cell RNA sequencingAberrant inflammationCell RNA sequencingSkin disease pathogenesisDisease pathogenesisManufacturer's guidelinesIndicators of diseaseDiseaseSpatial transcriptomics platformSkinTissue processing